For decades, patients with advanced or recurrent endometrial cancer had few options for systemic treatment and a generally poor prognosis. This outlook has changed recently with the development of novel targeted therapies that have expanded the options for treatment and improved response and survival compared to traditional approaches. Identifying appropriate patients for these agents requires an understanding of endometrial cancer molecular characteristics, individual patient factors that may influence response or toxicity, and an ability to educate patients and their families on the potential benefits and risks of approved and investigational agents in advanced clinical trials. This interactive CE/CME activity challenges learners to assess their knowledge of this rapidly evolving clinical landscape and to deepen their knowledge of novel approaches to disease control and toxicity management for women.
eNewsletter with interactive benchmarking
After completing this activity, participants should be better able to:
- Identify current and emerging recommendations for molecular profiling in endometrial cancer (EC) and their potential implications for prognosis and treatment
- Review evidence for novel agents for advanced or recurrent EC, including potential treatment selection factors
- Develop team-based strategies to address challenges to optimal treatment, including identification and management of side effects of novel agents
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
CNE course advisor: Katie Zahasky, NP
AAPA Credit Designation
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until August 15, 2020. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Heather M. Hylton, PA, Memorial Sloan Kettering Cancer Center, New York, New York
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Eisai, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Monk: consultant: AbbVie, Advaxis, Agenus, Amgen, ChemoCare, ChemoID, Conjupro, Eisai, Geistlich, Genmab, ImmunoGen, Immunomedicas, Incyte, Mateon, Merck, Myriad, Nucana, Oncomed, Oncoquest, Oncosec, Perthera, Pfizer, Precision Oncology, Puma, Samumed, Takeda, VBL; consultant/speaker: AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro, Inc.
None of the members of the Planning Committee, CE Alliance staff, or independent reviewer have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 15, 2019
Expiration date: August 15, 2020
© 2020 Practicing Clinicians Exchange. All Rights Reserved. OPCE94719-7B